CKD & Osteoporosis Rx Revisited (7.25.2025)
Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com.
Read Article
French retrospective observational study of Bx/CT/PET Dx of 380 #GCA pts found 7.6% (29) w/ Nl baseline CRP < 10 mg/L at Dx. GCA w/ low CRP had less fever, more ocular Dz (ant ischemic optic neuropathy 28 vs 13%), & limb claudication (24 vs. 8%) but equal relapse rates https://t.co/fPy92NjJzS
Dr. John Cush @RheumNow( View Tweet )
Clinical Associations with Anti-RNA Polymerase III Antibodies
A systematic review of anti-RNA polymerase III antibodies (ARA) in systemic sclerosis (SSc) patients finds ARA positivity in only 9% of SSc patients, but come with a higher risk of many potentially worrisome https://t.co/p1KVUFPJvN
Dr. John Cush @RheumNow( View Tweet )
Manifestations and Treatment in Relapsing Polychondritis
A large multicenter cohort study of Relapsing Polychondritis (RP) describes the clinical manifestations and treatment approaches to this rare, heterogeneous, multisystem disease.
https://t.co/Gz2qwtC4jZ https://t.co/llK9W45DlW
Dr. John Cush @RheumNow( View Tweet )
Manifestations and Treatment in Relapsing Polychondritis
A large multicenter cohort study of Relapsing Polychondritis (RP) describes the clinical manifestations and treatment approaches to this rare, heterogeneous, multisystem disease.
https://t.co/Gz2qwtC4jZ https://t.co/ZLkjNQmbRC
Dr. John Cush @RheumNow( View Tweet )
Manifestations and Treatment in Relapsing Polychondritis
A large multicenter cohort study of Relapsing Polychondritis (RP) describes the clinical manifestations and treatment approaches to this rare, heterogeneous, multisystem disease
Overview of the VEXAS Syndrome
A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome.
Read Article
ICYMI: EGPA in 2025
Formerly classified as an ANCA-associated vasculitis, EGPA is both most commonly ANCA negative and clinically different to the other two ANCA-associated vasculitis conditions, GPA and MPA. The management of EGPA has frequently fallen into the trap of being copied from its more common and well-
Read Article
A Review of Intracranial GCA
A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes. https://t.co/NkN4gfcq3n
Dr. John Cush @RheumNow( View Tweet )
PCR: Prevalence, Cost, & Risk (6.27.2025)
Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com
Read Article
A Review of Intracranial GCA
A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes.
A systematic review included 102
EULAR 2025 – Day 3 Report
Highlights from Day 3 included presentations on imaging in vasculitis, a debate on treating high-risk pre-clinical RA, and EULAR Recommendations on ILD treatment, physical activity for arthritis, the EULAR disease activity score for antiphospholipid https://t.co/FAaj443wPX
Dr. John Cush @RheumNow( View Tweet )
Add-on certolizumab in pregnant women with APS
Women with antiphospholipid syndrome and lupus anti-coagulant are at high risk of developing adverse pregnancy outcomes (APO). Usual care includes low molecular weight heparin (LMWH) and low dose aspirin (LDA). Despite these therapies, APO have been reported up to 40%. An important
Read Article
Management of AAV:
1.High dose GC f/b reduced dose taper ‼️caution in pts w/severe renal dz and RTX induction.
2. RTX effective for induction and maintenance, best for relapses.
3.PLEX: in RPGN pts if accesible ⚠️ risk for infection.
4.Avacopan: for faster GC weaning. No https://t.co/kfZ4gM38KG
Links:
Adela Castro @AdelaCastro222( View Tweet )
Pearls on EGPA:
1. GC are mainstay for mild
dz
2. Organ threatening/relapsing➡️CYP (RTX alternative)
3. W/o organ threatening➡️ anti-IL-5/IL-5R.
4. IL5i are less effective for ENT
5. Consider sx for nasal polyps.
#EULAR2025 @RheumNow https://t.co/zoJEWxafsN
Links:
Adela Castro @AdelaCastro222( View Tweet )
Manifestations of relapsing polychondritis
@Lupusreference @RheumNow #EULAR2025 https://t.co/EuPOdKKjax
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#ClinicalPearls
For
#cartilage #swelling in #relapsing #polychrondritis
Ask for #pics
#Levamisole in #cocaine
#infection - uncommon - from piercing
Acute #bacterial v chronic
#lymphoma
#malignancy
#vasculitis
#Trauma
Hx, duration, fever can be helpful
#EULAR2025
@RheumNow https://t.co/X2b6VHYsYa
Links:
Janet Pope @Janetbirdope( View Tweet )
#Relapsing_Polychondritis
Main differential diagnosis is GPA
🔺️No ANCA and no renal involvement in relapsing polychondritis
@Lupusreference
#EULAR2025
@RheumNow https://t.co/QUJZ3EDjj3
Nelly ZIADE 🍀 @Nellziade( View Tweet )
Tips for Dx RP:
1. Suspect the dx and recognize chondritis.
2. Rule out mimickers
3.Tracheal involvement shows swelling>stenosis (helps ≠from GCA)
4. CV, heme, derm manifestations 🧐VEXAS.
5. biopsy not useful unless ≠ from GCA.
Fantastic session by @Lupusreference https://t.co/W4DgfeRULF
Links:
Adela Castro @AdelaCastro222( View Tweet )
Great talk by @Lupusreference on Relapsing Polychondritis and a highlight of #EULAR2025. Do not forget about the articular presentations of relapsing polychondritis @RheumNow https://t.co/1xZY7VkX1z
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Rheumatoid vasculitis: what to look for and how to find it
#EULAR2025 @AshimaMakol @RheumNow https://t.co/ZCUXgOr1dH
David Liew @drdavidliew( View Tweet )
How to treat rheumatoid vasculitis
#EULAR2025 @AshimaMakol @RheumNow https://t.co/A8oqPd6bJx
David Liew @drdavidliew( View Tweet )
What kills in GCA?
Greek national prospective cohort, small numbers and no doubt some channeling bias, but:
Steroids (absence of DMARD use) is more of a factor than CV disease in GCA mortality.
With new options, all GCA pts should be on something
#EULAR2025 POS0960 @RheumNow https://t.co/Wmvf6tEvaF
David Liew @drdavidliew( View Tweet )
Safety of Recombinant Zoster Vaccine in Rheumatic Patients
EurekAlert!
New work presented at the 2025 annual EULAR congress in Barcelona focuses on the recombinant zoster vaccine (RZV), which contains recombinant glycoprotein E – the major target of CD4+T-cells. The abstract describes the tolerability and safety of RZV in patients with inflammatory rheumatic and
Read Article
#ANCA #vasculitis is not created equally
REVEAL cohort 588 ANCA
Initial & 12 months #BVAS (activity index)
mean ⬇️BVAS over 1 yr in all groups
#GPA #MPA #eGPA
5yr survival not = over time
⬆️survival in eGPA & GPA vs MPA
#POS0329 #EULAR2025 @RheumNow @eular_org https://t.co/cUKytqNZnS
Links:
Janet Pope @Janetbirdope( View Tweet )
Recent Blogs
